Level of zero healthA launch of medical devices based on women, aimed at splitting the new soil, developing a device for continuous hormone monitoring, closed a overprotected round of funding of $ 6.9 million, despite the fact that it was just more than a year. Starting wants to remove the need for invasive blood tiers and support research that could lead to new treatments for conditions associated with hormone imbalances or even new healthcare innovations, such as individual dosage for contraception Base hormones.
“One of our investors told us that there are companies that create fundamental technologies and there are companies that create wrappers around this technology. You are creating new technology here,” says co -founder and Managing Director Ula Rustamova, discussing company growth since then We have the latest check -in with them last fall, when they presented themselves on stage on TechCrunch Disprring as part of the Battlefield Startup competition.
“The goal is to create a completely new market out of it, right? In the same way CGMS [continuous glucose monitors] did. Literally, from nothing, they created a market for many billions of dollars, “he continues. And they have a ripple phenomenon in the coming decades. “
Step by step
Building a completely new product category of any lane can take time. Factor to this material starting and a medical device for startup, is clearly zero health level will not be able to serve a displacement of the example in the way hormones are monitored at night.
This is why the team also works on a single use product (which is portrayed above in original form), which hope to be cleared for a prescription next year-to support intermittent hormone tests associated with medical cases Use such as fertility (IVF) and low testosterone (TRT).
The current original portable contains tiny needles that allow it to take samples just below the skin to detect hormone trace elements.
This is a step towards monitoring the hormone that is eventually worn hoping to bring to the market – temporarily paved for 2028 – this is able to draw a continuous measure of things such as progesterone, estrogen and testosterone from the intermediate fluid of the user. (This is liquid that fills the spaces around the cells, acting as an intermediate between blood plasma and cells – so because biochemical compounds in the blood can also be detected in median fluid.)
A continuous hormone monitoring device – or, rather, the data it gets – could play a transformative role in enhancing the scientific understanding of the roles played by hormones in human biology – as well as CGMs have converted diabetes management (and more outside his).
However, the Zero Health level is also a B2B business-building building with the aim of selling technology to health care networks-so that the founders work in twin product growth to reduce market time and bridge The gap between Big Bang Mission and what is possible.
“We think we have this source of the truth we can make use of – which is a median liquid,” says Rustamova TechCrunch. “And we believe that there is an immediate, smaller product here to start first.
‘The idea is this constant [hormone monitoring] … It’s the Holy Grail – this is the future – because it makes sense, somehow, because it is again without friction, you can put it on, and you can get really consistent measurements. But we also understand that today, we have to enter the market in a way that we will not try to change the protocol-and have no seven-year research question “Let’s try to interpret this data”-so our first device is actually similar With finger devices, but it is also a patch. ”
The original costume is able to take measurements throughout the day when worn-by-out of a series of data points aimed at “delivery of value immediately” for cases such as IVF, where a woman would need to have multiple Blood calls for monitoring hormone levels.
Rustamova reports that the team hopes to have completed clinical trials and secure clearance for this single intermittent follow-up of next year-with eyes to obtain approval from both the US regulatory authority, the FDA, and the CE marking that It will allow them to sell markets in European health (it says they are not sure that they may come first).
“Hopefully this year we want to show some level of correlation [between levels of hormones the wearable patch can detect and levels detected via a blood draw] -This is the promise I want to deliver with the pre-service money, “he adds.
CTO and co -founder, Irene Jia, tells us that the goal of the team is to be able to show a 90%+ correlation with what their patch can get compared to the levels of hormones of the blood tie.
Risk for reward
Although later-when we are discussing the delay between blood-based measurements and detection through median fluid-Rustamova hits to emphasize the difference in medical risk between CGM and hormone monitoring. He points out that the risk for someone with diabetes (that is, if blood glucose readings are delayed or disabled) is likely to be extremely high, while hormone monitoring is not typically so high stakes.
“For glucose, you have possible fatal consequences to give the wrong reading or have this delay … [but when it comes to hormone monitoring] The risk of having a slight deviation or kind of correlation that is not so tight, “he tells us.” Obviously, we will try to associate as much as possible – but … there is this very different risk profile here. “He also noted that the First CGMS on the market had a lower association with blood readings than these devices now.
The proposal is the goal of the team is to continue to increase the bar accurately. Which – perhaps – implies that investors were willing to accumulate in this early round of Medtech Startup – with possible rewards against the dangers in a positive direction.
The other – undoubtedly – useful factor here is that the level of zero health does not focus solely on women’s health issues. Monitoring male hormones is a key part of the original business plan. (And the case remains that most technology investors are still men who place bets to solve problems that speak in their interests.)
Health Health Level Health’s Pre-Seed Funding Round was led by European VC Redalpine. Hax (SOSV), the entrepreneur (EF) and the experts of the industry also contributed to the round – with SOSV having previously accepted the start to the Deteptech/Hardware Hax and Rustamova was also an alum EF.
Commenting on a statement, Philip Kneis, a Redalpine investor and a member of Health Health’s Board of diagnostics and as fundamental transitions of science to Engineering, we could not be more excited by returning zero health into their mission to convert hormone monitoring with their novel Biomedical Sensor – paving the way for a new era. Health. “
